Camlin Fine Sciences Limited announced its audited financial results for the quarter and year ended March 31, 2026, during the Board Meeting held on May 26, 2026. The company reported a decline in standalone revenue from operations for the quarter ended March 31, 2026, compared to both the previous quarter and the corresponding quarter of the previous year.
Financial Result Analysis (Standalone – Rs. in Lakhs)
| Particulars | Q4 FY26 (Mar 31, 2026) | Q3 FY26 (Dec 31, 2025) | Q4 FY25 (Mar 31, 2025) | QoQ Growth (%) | YoY Growth (%) |
|---|---|---|---|---|---|
| Revenue from Operations | 18,351.65 | 21,892.16 | 27,259.63 | -16.17% | -32.68% |
Note: The financial growth figures above are calculated based on the standalone revenue from operations figures extracted from the audited financial results provided.
Camlin Fine Sciences Limited is a global player in the specialty chemicals industry, recognized for its expertise in antioxidants and downstream products of catechol and hydroquinone. The company serves a diverse clientele across more than 80 countries in the pharmaceutical, petrochemical, and agrochemical sectors. Recent business developments in 2025 included the acquisition of a 78.68% stake in Vinpai SAS, a transaction completed on November 27, 2025, to strengthen its market position. In its latest corporate updates, the company announced the appointment of Mr. Pankaj Pandey as the new Chief Financial Officer, effective August 18, 2026, while the current CFO, Mr. Santosh Parab, will transition to the role of President – Strategy and Global CFO.
Leave a Reply